Fig. 3

Passive transfer of anti-CSP mAbs reduce liver stage burden of transgenic P. berghei in mice. BALB/c mice were injected with 25 µg (250 µg/ml), 12.5 µg (125 µg/ml), and 2.5 µg (25 µg/ml) of anti-CSP mAbs (n = 4 per group) 30 min before the challenge with 5 × 10³ sporozoites via tail vein injection. Representative images of a PbmCh-luc and d Pb-PfCSP(r)-infected mice quantified at 44 hpi by b, e qRT-PCR and bioluminescent imaging. No antibody-treated mice (n = 4) were used to normalize data for c, f percent inhibition. Results are represented as median ± 95% CI for each experimental group. Statistical significance was calculated using a Kruskal–Wallis test with Dunn’s multiple comparisons and defined as P < 0.05 (*) and P = 0.0099 (**)